All members of our team have extensive knowledge and experience in imaging endpoint process standards of clinical trials. Our key players include expert project managers, imaging specialists, data management personnel, data quality evaluators, quality assurance staff, and adept software developers....
MERIT attended the WG-09: Ophthalmology meeting at AAO 2022. Read our article for several key takeaways. ...
MERIT’s webinar provides key takeaways that are important for oncology imaging clinical trials along with insights on how an Imaging Core Lab (ICL) can help you address imaging trial challenges. ...
Learn about the principles and recommendations of RANO response criteria for high grade glioma (HGG) and the imaging endpoint information that needs to be collected for clinical trials....
In this article, learn about the key role that IRCs play in imaging clinical trials....
Key takeaways from MERIT's Webinar: RECIST 1.1 and Oncology Trial Endpoints. ...
Imaging provides an unbiased, structural assessment of many disease states, which is a complement to functional outcome measures...
Globally, over 70,000 people are living with the often-debilitating effects of CF. While CFTR modulator treatments offer benefits for many, those with nonsense mutations require new therapies. ...
ETDRS BCVA is the primary endpoint for many, if not most, ophthalmic clinical trials. Learn about novel endpoints for visual function testing in this article. ...
Effective treatments for GBM remain a large unmet need in oncology. Developing an effective treatment is difficult due to many factors, including localization of tumors in the brain, resistance to therapy, migration of malignant cells into nearby brain tissue, and the blood-brain barrier. ...
CAR T-cell therapy for blood cancers may provide long-term remission for some patients, but their clinical benefit is limited by the complexity and cost of manufacturing and lack of efficacy in solid tumors. New developments in the field, however, offer hope to patients of greater...
Since the FDA approved ipilimumab, the first monoclonal antibody (MAB) blocking the immune checkpoint CTLA4, in 2011, immune checkpoint inhibitors have become some of the most widely prescribed anticancer treatments....